Conference Coverage
Conference Coverage
Crohn’s disease remission rates ‘remarkably higher’ with vedolizumab
Findings may influence physicians to select vedolizumab over anti-TNF therapy as first-line biologic for CD.
Conference Coverage
Mental health risks higher among young people with IBD
“Anxiety and depression will not be a surprise to most of us. But we also saw changes for eating disorders, PTSD, and sleep changes.”
Conference Coverage
DNA panels could predict endoscopic response to biologics in Crohn’s disease
Adding biomarkers to improve biologic medication selection is “urgently needed ... however, such biomarkers are not available for practice today...
Conference Coverage
Ileocecal resection possible first-line option in early Crohn’s disease
Patients with early ileocecal Crohn’s disease who undergo ileocecal surgery remain off drug treatment 5 years later.
Conference Coverage
Pediatric IBD patients wrestle with lingering gut pain
Chronic pain in children and adolescents with IBD is not linked to disease activity, nonetheless it impacts emotional wellbeing which suggests...
Conference Coverage
IBD: More patients on vedolizumab vs. anti-TNFs at 2 years
Vedolizumab showed a higher overall 1- and 2-year persistence of use, compared with two anti–tumor necrosis factor inhibitors in both Crohn’s...
Conference Coverage
Cannabis tied to lower IBD mortality, hospital costs
Patients with inflammatory bowel disease who concurrently use cannabis show a highly significant reduction in inpatient mortality and hospital...
Conference Coverage
Consider cultural differences in IBD diet planning
Clinicians should incorporate culturally sensitive discussions and recommendations into interactions with patients with inflammatory bowel disease...
Conference Coverage
Herbal combination tames active UC in small study
Derivatives of an intensely yellow spice and an intensely blue dye combined to resolve active ulcerative colitis in a small randomized trial.
Conference Coverage
Adult stem cells can heal intractable perianal Crohn’s fistulae
Many patients experienced complete healing within 3 months of a single infusion of mesenchymal stem cells.